Publications by authors named "E M Bekers"
Article Synopsis
- The study aimed to investigate imaging biomarkers for tumor response in patients with intermediate/high-grade soft tissue sarcomas (STS) following neoadjuvant radiotherapy (nRT), focusing on changes in imaging and pathology.
- The analysis involved 107 patients, measuring tumor characteristics like diameter, volume, and signal intensity before and after treatment, and correlated these with pathological outcomes such as necrosis and viable cell percentage using statistical methods.
- Results showed a low rate of complete tumor response, with specific subtypes like myxoid liposarcoma and undifferentiated pleomorphic sarcoma exhibiting significant changes in tumor size and signal intensity related to necrosis and fibrosis post-radiotherapy.
Correction: Multispectral Fluorescence Imaging as a Tool to Distinguish Pelvic Lymphatic Drainage Patterns During Robot-assisted Lymph Node Dissection in Prostate Cancer.
Anne-Claire Berrens Tessa Buckle Matthias N van Oosterom Leon J Slof Pim J van Leeuwen Elise M Bekers
Ann Surg Oncol
December 2024
ASO Visual Abstract: Multispectral Fluorescence Imaging as a Tool to Distinguish Pelvic Lymphatic Drainage Patterns During Robot-Assisted Lymph Node Dissection in Prostate Cancer.
Anne-Claire Berrens Tessa Buckle Matthias N van Oosterom Leon J Slof Pim J van Leeuwen Elise M Bekers
Ann Surg Oncol
February 2025
Background: The invasive nature of extended pelvic lymph node dissection (ePLND) prompts the need for alternative lymphatic mapping technologies. To change the focus to "sparing nodes that are not involved," the first step is to research the feasibility of intraoperatively distinguishing the lymph drainage patterns of the prostate from healthy organs.
Methods: We performed a prospective study (NCT05120973) that included 16 patients who underwent a robot-assisted radical prostatectomy + ePLND + sentinel node (using indocyanine green-Tc-nanocolloid).
Article Synopsis
- - Phenotypic plasticity in cancer, particularly prostate cancer (PCa), leads to resistance against androgen receptor-targeted therapies, highlighting the need to understand its driving mechanisms to prevent resistance emergence.
- - The study found that loss of the tristetraprolin (TTP) gene (ZFP36) increases NF-κB activation, correlating with more aggressive disease and recurrence, especially when PTEN, another key driver in PCa, is also lost.
- - Targeting the NF-κB pathway with an inhibitor (DMAPT) showed promising therapeutic effects in tumors exhibiting co-loss of ZFP36 and PTEN, suggesting a potential new treatment strategy for castration-resistant PCa.